Wall Street Zen downgrades Soleno Therapeutics to 'Hold' rating

Analysts cite concerns over the company's future performance and growth prospects.

Mar. 22, 2026 at 5:18am

Got story updates? Submit your updates here. ›

Wall Street Zen, a prominent research firm, has downgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from a 'Buy' rating to a 'Hold' rating in a recent note to investors. The downgrade comes as analysts express concerns over the company's future performance and growth prospects, despite its lead candidate DCCR being investigated for the treatment of Prader-Willi syndrome.

Why it matters

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases. The downgrade from Wall Street Zen could impact investor sentiment and the company's ability to secure funding and partnerships, which are crucial for the advancement of its pipeline, including the DCCR program for Prader-Willi syndrome.

The details

In their research note, Wall Street Zen analysts cited several factors that led to the downgrade, including a reduction in the company's price target from $114 to $110 and a shift in the overall rating from 'Buy' to 'Hold'. The analysts noted that while Soleno Therapeutics' lead candidate DCCR shows promise, there are concerns about the company's ability to execute on its development plans and achieve its growth targets.

  • Soleno Therapeutics was downgraded by Wall Street Zen on Sunday, March 22, 2026.

The players

Wall Street Zen

A prominent research firm that provides investment analysis and recommendations to its clients.

Soleno Therapeutics

A clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases, including its lead candidate DCCR for the treatment of Prader-Willi syndrome.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The downgrade of Soleno Therapeutics by Wall Street Zen highlights the challenges facing the company as it seeks to advance its pipeline and secure funding for its development programs. Investors will be closely watching the company's progress and its ability to address the concerns raised by the research firm.